Article
[Genetic testing of constitutive sensitivity to metformin in cancer patients with and without diabetes].
Voprosy onkologii - 1 Jan 2013
Bershteĭn L M, Vasil'ev D A, Ievleva A G, Imianitov E N
Abstract excerpt
Metformin (MF) belongs to the most popular andidiabetic medicines and is considered to possess a selective antineoplastic action. This selectivity at least partly may be explained by the certain features of MF pharmacogenetics. More than 150 postmenopausal females divided into 4 groups (cancer +diabetes type 2 (DM2); cancer without DM2; DM2 without cancer, and healthy) were studied. Genetic polymorphisms of the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
